Viamet Pharmaceutials

http://www.viamet.com/

Last activity: 04.01.2018

Probably Closed - Reference to

Categories: EdTechHealthTechLEDTechnology

Mentions

Overview

Location

United States, North Carolina, Durham

Employees

51-200

Total raised

$72M

Founded date

2004

Funding Rounds 3

Date	Series	Amount	Investors
Sign up to see	Sign up to see	Sign up to see	Sign up to see
Oct 21, 2014	Series D round	$60M
Jun 7, 2007	Funding round	$4M

Mentions in press and media 25

Date	Title	Description
Sign up to see	Sign up to see	Sign up to see
Jan 3, 2018	NovaQuest Capital to Acquire Viamet Pharmaceuticals	RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–Viamet Pharmaceuticals (NC), Inc. announced that it has entered into an agreement with NovaQuest Capital Management, L.L.C. for the acquisition of Viamet Pharmaceuticals, including the company’s ...
Mar 3, 2015	Angel investor involvement growing in North Carolina life sciences startup scene #CEDLSC15	“There’s been an uptick in undisclosed investors, and growth in syndicated angel investor funds,” Rose said. Notably, the majority of investment dollars come from outside North Carolina, with a huge chunk in California – though this include...
Dec 11, 2014	Viamet spinout Innocrin Pharma raises $8M for hard-to-treat prostate cancer	“There is urgent medical need for new therapies that effectively treat castration-resistant prostate cancer (CRPC) and for predictive diagnostics that identify those patients who will or will not benefit,” Scher said in a statement. “The pr...
Oct 21, 2014	Viamet Pharmaceuticals Closes $60M Series D Financing	Viamet Pharmaceuticals Holdings, LLC, a Research Triangle Park, North Carolina-based biopharmaceutical company, closed a $60m Series D financing. Backers included Brandon Point Industries Limited, Woodford Investment Management, which joine...
Oct 21, 2014	Viamet Announces $60M Series D Financing	RESEARCH TRIANGLE PARK, NC, Viamet Pharmaceuticals Holdings, LLC (Viamet) today announced the closing of a $60 million Series D financing. >> Click here for more funding data on Viamet >> To export Viamet funding data to PDF...
Feb 27, 2013	4 life sciences CEOs on lessons learned the hard way	Tim Willis, president, CEO and co-founder, TearScience: “We were out raising a series C, and we thought we had done our due diligence on the firms we were working with, and we assumed incorrectly that they had money to (do deals). I had fou...
Mar 8, 2012	Viamet hires former Icagen executive as chief business and financial officer	Katz brings to Viamet more than 15 years of pharmaceutical and life science investment banking experience. He most recently served as CFO of Icagen, a Durham drug development company that was acquired by Pfizer (NYSE:PFE) last year. Katz ha...
Feb 15, 2012	Pharmas, medical device makers set to pitch at CED Life Science conference	A total of 16 companies are scheduled to make presentations, split evenly between pharmaceuticals and medical devices. Here’s a quick rundown of the presenting companies, all of whom are either based in North Carolina’s Research Triangle or...
Nov 4, 2011	Novartis executive named Viamet’s first chief medical officer	“We are excited to have Dr. Rudoltz join the Viamet team,” Viamet CEO Robert Schotzinger said in a statement. “He will play a critical role as we transition from a discovery-stage company to a product-focused company.” In September, Viamet ...
Aug 17, 2011	‘Hatteras Discovery’ launches; up to $25M set for life sciences seed funding	With Hatteras’s first three funds, the firm has more than $120 million under management. Hatteras is still investing from its third fund, an $83 million early stage fund that invests in “breakthrough discoveries that impact human medicine.”...
Jul 28, 2011	Novel antifungal from Viamet selected for NIH rare diseases drug program	Cryptococcal meningitis is a fungal infection that affects the membranes covering the brain and spinal cord. It afflicts more than 1 million people in the developing world annually and kills about 500,000, according to research reports. Via...
Jun 9, 2011	N.C. startup activity gets boost from Carolina KickStart	“This is sort of a dating game; get to know people,” Rose said. “They may get involved in some way. You don’t want to get married. You just want to get to know each other.” But these are meetings with purpose and at some point down the line...
Jan 19, 2011	Cancer expert and former FDA leader von Eschenbach named to Viamet board	Promoted Covid-19’s terrible toll on diabetes patients. What can be done? The public health crisis has undermined the economy and made people with chronic conditions more vulnerable and stressed. Learn more with a new report from Omada Heal...
Jun 7, 2007	Viamet raises $4M for metalloenzyme-targeting drugs	Research Triangle Park, N.C.-based Viamet raised $4 million in a first round of funding. The round was co-led by Hatteras Venture Partners and Intersouth Partners. Viamet is developing drugs that target metalloenzymes — a diverse group of c...
	Angel investor involvement growing in North Carolina life sciences startup scene #CEDLSC15	Angels and high net-worth individuals are making up a growing investment base for North Carolina’s startup sector – an interesting trend that shows that venture dollars are losing their pull in the funding game. The life sciences sector rai...
	Pharmas, medical device makers set to pitch at CED Life Science conference	Life science companies and investors, let’s make a deal. The annual CED Life Science Conference kicks off in Raleigh, North Carolina today where small drug developers hope to make the right connection with a big pharmaceutical company or ve...
	Viamet hires former Icagen executive as chief business and financial officer	Drug discovery and development firm Viamet Pharmaceuticals has named a new top financial executive as the company readies two clinical stage compounds for potential drug partners. Dr. Richard Katz was appointed to the newly created position...
	Novel antifungal from Viamet selected for NIH rare diseases drug program	Viamet Pharmaceuticals will work with the National Institutes of Health to develop one of the company’s compounds into a treatment for the fungal infection cryptococcal meningitis. An antifungal compound from Morrisville, North Carolina-bas...
	4 life sciences CEOs on lessons learned the hard way	There are some lessons that no amount of reading can teach an entrepreneur. Sometimes, you just have to learn by doing. And that goes for companies at all stages, as a panel of CEOs at the CED Life Science Conference shared on Wednesday. Du...
	Cancer expert and former FDA leader von Eschenbach named to Viamet board	Viamet Pharmaceuticals has landed a healthcare heavyweight in naming prostate cancer expert and former U.S. Food and Drug Administration commissioner Dr. Andrew von Eschenbach to the company’s board of directors. Durham, North Carolina-base...
	‘Hatteras Discovery’ launches; up to $25M set for life sciences seed funding	Hatteras Venture Partners‘s fourth venture fund is closing in on its $125 million target and the venture capital firm has now formally launched the seed-stage portion of the fund, which will invest in seed-stage opportunities in medicine an...
	Novartis executive named Viamet’s first chief medical officer	Viamet Pharmaceuticals has hired a Novartis (NYSE:NVS) executive to become the company’s first chief medical officer. Dr. Marc Rudoltz will oversee development of Durham, North Carolina-based Viamet’s oncology and infectious disease therapi...
	N.C. startup activity gets boost from Carolina KickStart	If you want to feel the pulse of startup activity in North Carolina’s Research Triangle, consider visiting the Cafe Carolina in Chapel Hill. Many scientific discoveries start with chemistry. But here, companies start with coffee. On most mo...
	Viamet spinout Innocrin Pharma raises $8M for hard-to-treat prostate cancer	Innocrin Pharmaceuticals, the spanking-new spinout of successful antifungal company Viamet, just raised $8 million according to regulatory filings. The company has taken Viamet’s findings and translated them as a therapy for a tough-to-trea...

Reviews 0

FAQ about Viamet Pharmaceutials

When was Viamet Pharmaceutials founded?

Viamet Pharmaceutials was founded in 2004.

How much funding has Viamet Pharmaceutials raised?

Viamet Pharmaceutials has raised $72M in total across 3 funding rounds.

What funding rounds has Viamet Pharmaceutials raised?

Parsers VC lists 3 funding rounds of Viamet Pharmaceutials, among them a Series D round of $60M on Oct 21, 2014 and a funding round of $4M on Jun 7, 2007.

What has the press written about Viamet Pharmaceutials?

Parsers VC has collected 25 articles mentioning Viamet Pharmaceutials, among them “NovaQuest Capital to Acquire Viamet Pharmaceuticals” (Jan 3, 2018) and “Angel investor involvement growing in North Carolina life sciences startup scene #CEDLSC15” (Mar 3, 2015).

Is Viamet Pharmaceutials still active?

Viamet Pharmaceutials is probably closed: its latest activity on Parsers VC dates from Jan 4, 2018.